VKTX 주가 차트
VKTX 수입
Viking Therapeutics Inc
$31.71
0.03%
$0.01
종가: May 14, 16:00:00 GMT-4
$31.52
-0.59%
$-0.19
프리마켓: May 15, 04:16:28 GMT-4
뒤로
Viking Therapeutics Inc (VKTX) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-04-29
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
VKTX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Viking Therapeutics Inc VKTX의 지난 분기 매출 실적은 어땠나요?
Viking Therapeutics Inc의 매출 추정치는 얼마인가요?
Viking Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Viking Therapeutics Inc는 언제 수익을 보고하나요?
Viking Therapeutics Inc의 예상 수익은 얼마인가요?
Viking Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$31.7
시가
$31.78
일일 범위
$30.82 - $31.95
52주 범위
$22.95 - $43.15
거래량
1.4M
평균 거래량
2.7M
배당수익률
--
EPS(TTM)
-3.18
시가총액
$3.6B
VKTX란 무엇인가요?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 53 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
